Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	December 31,
	2024		2023
Rebates and other sales deductions	$	342,717	$	325,711
Employee compensation and benefits	153,133		121,209
Clinical trial accruals	49,962		44,757
Accrued interest	41,626		36,443
Accrued royalties	36,802		30,706
Accrued milestones	27,500		—
Selling and marketing accruals	26,981		14,743
Sales return reserve	26,428		20,435
Consulting and professional services	26,221		19,538
Inventory-related accruals	25,509		13,977
Accrued development expenses	23,099		15,431
Accrued collaboration expenses	18,005		10,158
Current portion of lease liabilities	14,779		19,447
Derivative instrument liabilities	10,198		681
Accrued construction-in-progress	10,061		5,141
Accrued facilities expenses	6,107		55,455
Other	71,819		60,082
Total accrued liabilities	$	910,947	$	793,914